University Urology, PC
1928 Alcoa Highway, Suite B-222
Knoxville, TN 37920
Website: University Urology, PC
Certification: American Board of Urology
Schools: University of Tennessee College of Medicine
Internships: University of Tennessee Medical Center
Residencies: University of Tennessee Medical Center
Fellowships: Cleveland Clinic
- Minimally Invasive Surgery
- Single Port Surgery
- Director of Laparoscopic and Robotic Urologic Surgery
- Gettman MT, White WM, Aron M, Autorino R, Averch T, Box G, et al: Where Do We Really Stand With LESS and NOTES? Eur Urol 2010; Epub ahead of print.
- Hardin BM, White WM, Clark CT, and MacLennan GT: Urinary Schistosomiasis. J Urol 2010; 184: 2136-2137.
- Kaouk JH, Goel RK, White MA, White WM, Autorino R, Haber GP, and Campbell SC: Laparoendoscopic Single-site Radical Cystectomy and Pelvic Lymph Node Dissection: Initial Experience and 2-Year Follow-up. Urology 2010; 76: 857-861.
- Haber GP, White WM, Crouzet S, White MA, Forest S, Autorino R, and Kaouk JH: Robotic Versus Laparoscopic Partial Nephrectomy: Single-surgeon Matched Cohort Study of 150 Patients. Urology 2010; 76: 754 - 758.
- White WM and Kim ED: Evolving role of 5-a reductase inhibitors in chemoprevention. Nat Rev Clin Onc 2010; 7: 487 - 488.
- First Prize - Audiovisual Award, American Urological Association Annual Meeting, 2009.
- Olympus Prize for Best Overall Paper - 26th World Congress of Endourology Annual Meeting, 2008.
- CaPSURE Scholarship, 2007 - 2008
- 3rd Place, T. Leon Howard Pyelogram Conference - Southeastern Section, AUA
- Kimball I. Maull Research Award, The University of Tennessee Department of Surgery, 2006.
- Gore Honors Scholarship, The University of Tennessee College of Medicine, 1999 - 2003
- Outstanding Research Award, The University of Tennessee College of Medicine, 2002
- College Scholars Honors Program, The University of Tennessee, Knoxville, 1996 - 1999
- Phi Beta Kappa, The University of Tennessee, Knoxville, 1999
- I. Reid Collmann Research Scholarship, The University of Tennessee Graduate School of Medicine
- Eagle Scout, Boy Scouts of America, 1995
- Society of Urologic Oncology
- Society of University Urologists
- Endourological Society
- American Urologic Association
- Robotic Renal Surgery
- Single Port and Natural Orifice Surgery
- Tennessee Athletics
From Dr. White:
The American Cancer Society (ACS) estimates that approximately 240,000 men in the United States will be diagnosed with prostate cancer in 2012. The ACS further estimates that approximately 28,200 men will die of prostate cancer this year. These figures represent an overall increase in the annual number of new cases as well as a decrease in the number of prostate-cancer related deaths.
Although controversial, many urologists credit the introduction and widespread adoption of Prostate Specific Antigen (PSA) testing as a driving factor in not only detecting more cases of prostate cancer, but also detecting them at an earlier and, in most cases, a more treatable stage. Indeed, several large studies that enrolled many thousands of men have found PSA testing to be of benefit with regards to cancer detection. Still others have demonstrated a significant reduction in the risk of dying from prostate cancer if a man is screened appropriately.
Despite these compelling studies, conflicting data also exists that questions whether prostate cancer is potentially â€˜over diagnosedâ€™ and that many men with non-lethal prostate cancers are subjected to unnecessary treatment and treatment-related side effects. Unfortunately, screening often identifies men with very early stage prostate cancer or with tumors that are not inherently very aggressive. Many of these men will ultimately seek treatment. In these situations, we as urologists often wonder how much benefit we are providing. This rationale is behind the recommendations of the United States Preventative Task Force (USPTF) that prostate cancer screening is not beneficial and is not recommended. Unfortunately, following these recommendations without an alternative or better screening tool than PSA may bring us back to the pre-PSA era during which men came to their doctors with advanced disease that was often incurable. Moreover, we may never find those men with inherently more aggressive disease that needs to be treated and can be potentially cured if detected early enough.
With all of this controversy and conflicting information, what are our recommendations?
The American Cancer Society recommends that beginning at age 50, men at average risk who have a life expectancy of at least 10 years should receive information about the benefits and risks of screening and have an opportunity to make an informed decision. Men at high risk (African American or a family history) should have a discussion with their healthcare provider beginning at age 45.
The American Urological Association Foundation believes every man needs to discuss prostate cancer screening with his physician starting at the age of 40 and at-risk men (family history of prostate cancer, African-American men) should discuss prostate cancer screening with their physician starting at the age of 35.
At the University of Tennessee Medical Center, prostate screening is offered to men who wish to be screened starting at age 40.
Meanwhile, urologists will actively look for a better and more reliable screening test that may help differentiate which men need to be screened, which men need to be treated, and which men can be observed.
Wesley M. White, M.D.
Director of Laparoscopic and Robotic Urologic Surgery
University Prostate and Urology Cancer Center
The University of Tennessee Medical Center, Knoxville